 Anti-HIV Agents
"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 4 | 4 | 8 | | 1999 | 5 | 3 | 8 | | 2000 | 4 | 0 | 4 | | 2001 | 4 | 1 | 5 | | 2002 | 3 | 0 | 3 | | 2003 | 2 | 1 | 3 | | 2004 | 9 | 1 | 10 | | 2005 | 7 | 3 | 10 | | 2006 | 5 | 2 | 7 | | 2007 | 5 | 1 | 6 | | 2008 | 9 | 2 | 11 | | 2009 | 9 | 3 | 12 | | 2010 | 11 | 2 | 13 | | 2011 | 9 | 9 | 18 | | 2012 | 19 | 2 | 21 | | 2013 | 13 | 3 | 16 | | 2014 | 20 | 6 | 26 | | 2015 | 12 | 4 | 16 | | 2016 | 31 | 10 | 41 | | 2017 | 26 | 9 | 35 | | 2018 | 22 | 6 | 28 | | 2019 | 14 | 6 | 20 | | 2020 | 27 | 6 | 33 | | 2021 | 36 | 5 | 41 | | 2022 | 36 | 0 | 36 | | 2023 | 32 | 2 | 34 | | 2024 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Kousari AE, Wilson MP, Hawkins KL, Bandali MM, Henao-Mart?nez AF, Gardner EM, Erlandson KM. Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV. HIV Res Clin Pract. 2024 12; 25(1):2339576.
-
Cianelli R, De Santis JP, De Oliveira GC, Castro JG, Iriarte E, Baeza MJ, Thomas SO, Villegas N, Peragallo-Montano N. Feasibility and acceptability of SEPA+PrEP: An HIV prevention intervention to increase PrEP knowledge, initiation, and persistence among cisgender heterosexual Hispanic women. PLoS One. 2024; 19(1):e0296080.
-
Chi BH, Saidi F, Graybill LA, Phanga T, Mollan KR, Amico KR, Freeborn K, Rosenberg NE, Hill LM, Hamoonga T, Richardson B, Kalua T, Phiri S, Mutale W. A Patient-Centered, Combination Intervention to Support Adherence to HIV Pre-exposure Prophylaxis During Pregnancy and Breastfeeding: A Randomized Pilot Study in Malawi. J Acquir Immune Defic Syndr. 2024 01 01; 95(1):42-51.
-
Lovett A, Luder R, Lillis RA, Butler I, Siren J, Gomez S, Kamis K, Obafemi O, Rowan SE, Baral S, Clement ME. Client Perspectives on the Development of a Rapid PrEP Initiative at a Sexual Health Center in New Orleans, Louisiana. J Int Assoc Provid AIDS Care. 2024 Jan-Dec; 23:23259582241258559.
-
Pons-Faudoa FP, Di Trani N, Capuani S, Facchi I, Wood AM, Nehete B, DeLise A, Sharma S, Shelton KA, Bushman LR, Chua CYX, Ittmann MM, Kimata JT, Anderson PL, Nehete PN, Arduino RC, Grattoni A. Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques. J Control Release. 2024 02; 366:18-27.
-
O'Halloran JA, Parra-Rodriguez L, Goss CW, Agarwal M, Cooley S, Wu K, Westerhaus E, Presti R, Ances BM, Tassiopoulos K, Erlandson KM. Impact of Integrase Strand Transfer Inhibitors on Cognition in the HAILO Cohort. J Acquir Immune Defic Syndr. 2023 12 15; 94(5):437-444.
-
Huang Y, Zhang L, Karuna S, Andrew P, Juraska M, Weiner JA, Angier H, Morgan E, Azzam Y, Swann E, Edupuganti S, Mgodi NM, Ackerman ME, Donnell D, Gama L, Anderson PL, Koup RA, Hural J, Cohen MS, Corey L, McElrath MJ, Gilbert PB, Lemos MP. Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01. Nat Commun. 2023 Nov 28; 14(1):7813.
-
Lartey M, Ganu VJ, Tachi K, Yang H, Anderson PL, Langaee T, Ojewale O, Boamah I, Obo-Akwa A, Antwi K, Bushman LR, Ellison L, Kwara A. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression. AIDS. 2024 03 01; 38(3):351-362.
-
Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP, Anderson PL, Hendrix CW, Adeyeye A, Rooney JF, Rinehart AR, Cohen MS, McCauley M, Grinsztejn B. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV. 2023 12; 10(12):e767-e778.
-
Wu K, Koethe J, Hulgan T, Brown T, Bares SH, Tassiopoulos K, Lake JE, Leonard M, Samuels DC, Erlandson K, Haas DW. Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens. Pharmacogenet Genomics. 2024 Feb 01; 34(2):25-32.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|